Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines UK Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-uk-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due to its elimination from the single primary dose, with patient share expected to be made up by Menjugate and NeisVac-C.

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the UK from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in the UK

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

3 Disease Overview 12

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 15

3.2 Symptoms 17

3.3 Prognosis 18

4 Disease Management 19

4.1 Meningococcal Immunization Policy 20

4.2 United Kingdom 22

4.2.1 Meningococcal Immunization Recommendations and Policies 22

4.2.2 Clinical Practice 24

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=177526

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074